title: Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial.
abstract: In a multicentre phase III study of disseminated malignant melanoma performed in Sweden and Norway, 326 patients were randomised to receive treatment with the combination dacarbazine [DTIC] (D) and vindesine (V) with or without the addition of cisplatin (P). D was given intravenously (i.v.) at a dose of 250 mg/m2 days 1-5 every 4 weeks and V was given i.v. at a dose of 3.0 mg/m2 day 1 weekly. P was given i.v. at a dose of 100 mg/m2 day 1 every 4 weeks. There was no statistically significant difference in overall survival between the treatment arms (P = 0.22). Increased toxicity was observed in the treatment arm containing P of which leucopenia, alopecia and nausea/vomiting were the most pronounced. The median time to progression was significantly longer in patients treated with DVP (4.2 versus 2.2 months, P = 0.007). In conclusion, adding P to DV did not change overall survival but did significantly increase toxicity.
authors.affiliation: Department of Experimental Oncology, Karolinska Hospital, Stockholm, Sweden.
authors.forename: U
authors.initials: U
authors.lastname: Jungnelius
authors.forename: U
authors.initials: U
authors.lastname: Ringborg
authors.forename: S
authors.initials: S
authors.lastname: Aamdal
authors.forename: J
authors.initials: J
authors.lastname: Mattsson
authors.forename: U
authors.initials: U
authors.lastname: Stierner
authors.forename: C
authors.initials: C
authors.lastname: Ingvar
authors.forename: P
authors.initials: P
authors.lastname: Malmström
authors.forename: R
authors.initials: R
authors.lastname: Andersson
authors.forename: M
authors.initials: M
authors.lastname: Karlsson
authors.forename: K
authors.initials: K
authors.lastname: Willman
authors.forename: E
authors.initials: E
authors.lastname: Wist
authors.forename: G
authors.initials: G
authors.lastname: Bjelkengren
authors.forename: R
authors.initials: R
authors.lastname: Westberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011446:Prospective Studies; D012044:Regression Analysis; D012878:Skin Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome; D014751:Vindesine / Q000008:administration & dosage / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced
chemical_list: D003606:Dacarbazine; D002945:Cisplatin; D014751:Vindesine